Holding(s) in Company

RNS Number : 2343M
Hikma Pharmaceuticals Plc
26 January 2009
 

 



Notification of major interests in shares

 

LONDON, 26 January 2009 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

 

2

Reason for the notification

Yes/no

 

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached

 

 

An event changing the breakdown of voting rights

 

 

Other (please specify): Compliance with the Transparency Directive

 

 

3

Full name of the person subject to the notification obligation

Legal & General Group Plc (L&G)

4

Full name of shareholders if different from above

-

5

Date of the Transaction (and date on which the threshold crossed is reached differently)

22 January 2009

6

Date on which the issuer notified

23 January 2009

7

Threshold that is crossed

Below 3% (L&G)

8

Notified details

 

 

A. Voting rights attached to shares

Class type of shares (if possible using the ISIN code)

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

Direct 

Indirect

Ordinary Shares (0.10 GBP)

5,181,598

5,181,598

Below 3%

 

B. Financial instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights that may be acquired if the instrument if exercised/converted

% of voting rights

 

 

 

 

 

 

Total A+B

Number of Voting rights

% of voting rights

Below 3%

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

 

Legal & General Group Plc (Direct and Indirect) (Group)  

 

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)  

 

Legal & General Investment Management Limited (Indirect) (LGIM) 

 

Legal & General Group Plc (Direct) (L&G) (Below 3% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) 

Legal & General Insurance Holdings Limited (Direct) (LGIH) 

Legal & General Assurance (Pensions Management) Limited (PMC)  

Legal & General Assurance Society Limited (LGAS & LGPL) 

 

Legal & General Pensions Limited (Direct) (LGPL)

 

 

Proxy Voting

 

10

Name of the proxy holder

N/A

11

Number of voting rights proxy holder will cease to hold

N/A

12

Date on which proxy holder will cease to hold voting rights

N/A

 

 

13

Additional Information

Notification using the total voting rights figure of  189,237,607

 

 

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Henry Knowles

Company Secretary

 

+44 20 7399 2760

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: 'Branded', 'Injectables' and 'Generics', based principally in the Middle East and North Africa ('MENA'), where it is a market leader and sells across 17 countries, the United States and Europe. In 2007, Hikma achieved revenues of $449 million and profit attributable to shareholders of $63 million. At 31 December 2007, the Group had over 3,000 employees. For news and other information, please visit www.hikma.com.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUNAARKARAUAR
UK 100

Latest directors dealings